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1. Introduction
Alzheimer's disease (AD) is an age-related disorder characterized by deposition of amyloid
β-peptide (Aβ) and degeneration of neurons in brain regions such as the hippocampus, re‐
sulting in progressive cognitive dysfunction. The causes of Alzheimer's disease (AD) have
not been fully discovered, there are three main hypotheses to explain the phenomenon: a)
The deficit of acetylcholine; b) The accumulation of beta-amyloid (Aβ and / or tau protein;
and c) Metabolic disorders.
The clinical criteria for diagnosing AD were defined in 1984 by the NINCDS-ADRDA; (Na‐
tional Institute of Neurological and Communicative Disorders and Stroke; Alzheimer's Dis‐
ease and Related Disorders). It states that for the diagnosis of disease is required to prove
the existence of chronic and progressive cognitive impairment in adults or elderly patients,
without other underlying causes that can explain this phenomenon. However, using this cri‐
terion, it is difficult to differentiate between AD and other causes of deterioration in early
stages of the disease.
© 2013 Ortiz et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
A number of recent research has been related AD with metabolic disorders, particularly hy‐
perglycemia and insulin resistance. The expression of insulin receptors has been demon‐
strated in the central nervous system neurons, preferably in the hippocampus. In these
neurons, when insulin binds to its cellular receptor, promotes the activation of intracellular
signaling cascades that lead to change in the expression of genes related to synaptic plastici‐
ty processes and enzymes involved in clearing the same insulin and Aβ. These enzymes de‐
grading of insulin promotes the reduction of toxicity due to amyloid in animal models.
People  with  neuritic  plaques  accumulate  in  brain  regions  that  correspond  to  brain  re‐
gions in healthy people that  rise  in a  metabolic  process  called aerobic  glycolysis.  While
some regions such as  prefrontal  and parietal  cortex,  which is  thought to have a role  in
self-recognition and control  tasks,  showed high levels  of  aerobic  glycolysis,  others  such
as  the  cerebellum and the  hippocampal  formation,  believed  to  affect  the  control  motor
and  memory,  showed  low  levels.  Brain  cells  use  aerobic  glycolysis  for  energy  derived
quickly from small amounts of glucose while obtaining the mass of its energy through a
biochemical process effective to burn glucose. Since aerobic glycolysis may help the brain
generate cell  constituents,  toxic metabolic byproducts manage and regulate programmed
cell death; the findings suggest a possible link between brain function that provides ener‐
gy to aerobic glycolysis and the onset of AD.
The causes of the late AD appear to be multifactorial, and cell biology studies point to cho‐
lesterol as a key factor in protein precursor of beta Amyloid (APP) processing and Aβ pro‐
duction. An alteration in cholesterol metabolism is attractive hypotheses, thus the carriers of
the Apolipoprotein E4 genes, which is involved in cholesterol metabolism, are at increased
genetic risk for Alzheimer's disease. Cholesterol is a component of cell membranes and par‐
ticularly is found in microdomains functionally linked to the proteolytic processing of APP.
In sporadic AD, a marked diminution of both membrane phospholipids and cholesterol has
been found.
Epidemiological studies indicate that mild hypercholesterolemia may increase the risk of
AD and decreased synthesis of cholesterol through statin administration can reduce the de‐
velopment of AD. Moreover, high cellular cholesterol content has been shown to favor the
production of Aβ. Genetic studies have suggested links between AD and cholesterol control
several genes including cholesterol acceptor ApoE (ε4 polymorphism). Liver X receptors
(LRXs) are ligand-activated transcription factors of the nuclear hormone receptor superfami‐
ly LXRs and also are expressed in the brain. LXRs stimulate the expression of genes in‐
volved in cellular cholesterol transport, regulation of lipid content of lipoproteins (apoE,
lipoprotein lipase, cholesterol ester transfer protein, and phospholipid transfer protein), me‐
tabolism of fatty acids and triglycerides (sterol regulatory element binding protein 1-c, fatty
acid synthase, stearoyl coenzyme A desaturase 1, and acyl coenzyme A carboxylase). Many
questions remain, but as a master regulator of cholesterol homeostasis, LXR may be consid‐
ered as a potential molecular target for the treatment of AD.
In summary, numerous studies on the role of cholesterol in AD suggest that high cholesterol
is a risk factor for early and late AD development.
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2. Dementia and pathological changes
Dementia is a syndrome that cause cognitive and memory alterations; problems of orienta‐
tion, attention, language and solving problems. Dementia involves a progressive decline in
cognition that goes above and beyond the normal changes that come with age due to inju‐
ries or brain diseases. The two most common causes of dementia are AD and vascular de‐
mentia. More than 33% of women and 20% of men aged 65 year or more will develop
dementia during their lifetime, and many more develop a milder form of cognitive impair‐
ment. Worldwide, the adult population is rapidly growing; prospective epidemiological
studies suggest that there will be an increase of 50% of the total number of people with cog‐
nitive disorders in the next 25 years. Dementia is associated with increased mortality and
disability, health care costs they mean a huge expenditure on health systems as well as a sig‐
nificant increase in social and economic responsibilities for caregivers and their families.
With a current affection about 10% of the population over the 65 year-old Alzheimer's dis‐
ease (AD) is the most common cause of progressive dementia [1].
AD is a progressive neurological disorder resulting in irreversible loss of neurons, partic‐
ularly in the cortex and hippocampus,  accounting for  about one third of  dementia syn‐
dromes,  with a range that  varies  from 42 to 81% of  all  dementias.  The clinical  findings
are  characterized  by  progressive  loose  of  memory,  loss  of:  judgment,  decision  making,
physical  orientation and language disorders.  The diagnosis  is  based on neurological  ex‐
amination and differential diagnosis with other dementias, but the definitive diagnosis is
made only by autopsy. The pathological findings at microscopic level are: neuronal loss,
gliosis, neurofibrillary tangles, neuritic plaques, Hirano bodies, granulo-vacuolar degener‐
ation of neurons and amyloid angiopathy [2, 3]. A very early change in AD brain is the
reduced glucose metabolism [4], and a recent analysis suggests that diabetes plays a role
in the acceleration of brain aging. But, although it is known that type 2-diabetes may be
associated with an increased risk of dementia, the exact mechanisms and mitigating fac‐
tors still  are not completely understood. The public  health implications of  this phenom‐
enon  are  enormous.  Although  initially  the  association  between  type  2  diabetes  and
vascular dementia appeared to be more consistent than the relationship between type 2
diabetes and AD, there are recent studies that have yielded more consistent evidence of
the relationship between diabetes and AD [5,6].
Neuritic plaques, neurofibrillary tangles and other proteins in AD brain are glycosylated
[7]. Since people with diabetes have an increased blood glucose level is plausible to sus‐
pect  that  they have a  higher chance of  having AD. Animal  models  of  induced diabetes
suggest a direct neurodegenerative effect of diabetes; most of these studies show damage
in the hippocampus, an area associated with learning and memory, and first structure to
be affected by the neurodegeneration of AD disease. A post-mortem study revealed that
people with diabetes and ApoE 4 allele, had more neuritic plaques and neurofibrilar tan‐
gles in the hippocampus and cortex,  also cerebral amyloid angiopathy, in which the as‐
sociated  protein  AD disease  is  deposited  on  the  walls  of  blood  vessels  in  the  brain.  It
has been shown that those with diabetes have a greater cortical atrophy, independent of
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hypertension,  the  blood  concentration  of  total  cholesterol,  smoking,  coronary  heart  dis‐
ease  and sociodemographic  factors  than people  without  the  condition.  Today we know
that  obesity  increases  the  risk  of  dementia  and  brain  atrophy.  However,  the  molecular
mechanisms that are behind metabolic disorders caused by excess body fat are not fully
understood yet, especially regarding its role in neurodegenerative diseases (see Figure 1).
Preliminary evidence suggests that some adipocytokines could cross the blood brain bar‐
rier, and have some function in learning and memory [8].
Figure 1. Abnormal metabolism increases risk for Alzheimer disease.
Recent findings from several longitudinal population studies have confirmed a link between
obesity and risk of dementia. People with a body mass index (BMI) indicating obesity (≥ 30)
have a greater probability of developing dementia (75%) compared with those with normal
BMI (18.5 to 24.9). We must emphasize that abdominal obesity is more closely associated
with dementia risk, that obesity spread throughout the body. Even for those with a healthy
weight, abdominal obesity increases the risk of dementia [9].
3. Insulin-cholesterol-AD
Insulin signaling in the central nervous system has gained much interest for his participa‐
tion in cognitive processes such as learning and memory and its possible relation to neuro‐
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degenerative diseases such as Alzheimer's disease. In peripheral tissues, mainly regulates
insulin metabolism energetic and cell growth. The insulin receptor and several components
of its signaling pathway are abundantly distributed in the mammalian brain and their acti‐
vation modulates neuronal growth and synaptic plasticity [10].
It has been suggested that some alterations in the insulin signaling appear to be responsible
for cognitive deficits and play an important role in the development of AD disease. Indeed,
Type II diabetes is a risk factor for developing this type of dementia. Recently it has been
observed that Aβ, which is overproduced in AD disease, causes alterations in the signaling
pathway of insulin, supporting the causal relationships between this condition interesting
and insulin [11]. In recent years the effects of insulin in the brain have drawn attention for
his participation in mental processes such as memory and learning. Insulin in the brain
plays an important role in the regulation of metabolism, and alterations in their activity are
directly related to metabolic diseases such as obesity, diabetes or metabolic syndrome. In the
mammalian brain, insulin anorexigenic effects, induces weight loss and regulates hypothala‐
mic control of food intake. Also regulates glucose homeostasis by stimulating peripheral
neurons producing pro-opiomelacortina (POMC) and agouti-related peptide (AgRP)
through the IR and PI3K [12, 13].
Insulin can be generated in different brain sites. It is known that insulin is produced in the
beta cells of the pancreas and can enter the brain through the blood brain barrier by active
transport mediated by IR. Furthermore, the presence of messenger RNA in mammalian
brain neurons, suggests that insulin can be produced locally. Likewise, there has been a
strict regulation of the levels of insulin and its receptor (IR) in the brain, which may suggest
that insulin level in the brain does not depend exclusively on the periphery [14]. However, if
the source is local cerebral insulin, peripheral or shared has not been clarified yet. The IR is
very abundant in the brains of rodents and humans with the highest concentration in the
olfactory bulb, the hypothalamus, pituitary gland, hippocampus, cerebral cortex and cere‐
bellum [15,16]. In addition, most of the proteins of the insulin signaling pathway have ex‐
pression patterns that overlap with the IR in the brain. The IR is found abundantly in the
hippocampus and its expression is increased after spatial learning tasks in rodents. The IR is
widely found in the synapses of the dendritic trees which regulate the release of neurotrans‐
mitters and receptor recruitment [17] (see Figure 2).
Insulin regulates glutamatergic and GABAergic receptors, through the activation of the
PI3K and MAPK. It is also known that the processes of long-term potentiation (LTP) and
long-term depression (LTD), are associated with the molecular events underlying the estab‐
lishment of memory and learning are regulated by the activation of PI3K through Complex
formation with NMDA receptors, which regulates PI3K NMDA receptor translocation to the
membrane. The response of the IR is reduced by the action of glutamate and depolarization,
probably involving calcium influx of Ca2+ and activation of Ca2+-dependent kinases (Figure
3). This suggests a possible role of insulin in the synaptic plasticity and modulation of neu‐
ronal activity [18-20].
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Figure 2. Insulin is produced in the Beta cells of the pancreasand enters the brain through the BBB ( Brain Blood Barri‐
er) via the IR (Insulin Receptor). Insulin levels on the brain do not depend exclusively on peripherical levels. The IR is
very abundant in the brain of rodents and humans, showing its highest concentration in the following areas (in de‐
scending order): Olfactory bulb, hypothalamus, pituitary gland, cerebral cortex, hippocampus and the cerebellum.
Most of the proteins involved in the insulin signaling pathway have expression patterns that overlap with the IR in the
brain [125].
The presence of components via postsynaptic regions, such as mTOR, p70S6K, eIF-4E, 4E-
BP1 and 4EBP2 suggest the existence of the regulation of protein synthesis at synapses. Insu‐
lin regulates the levels of the postsynaptic density protein PSD-95, which binds to the
NMDA receptors in the synaptic membrane, through mTOR activation and modulation of
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protein translation at synapses. Furthermore, mTOR modulates synaptic plasticity Thus, in‐
sulin not only modulates neuronal synaptic activity [21]
Different strategies can be proposed to prevent the characteristics of AD-related dysfunction
of the insulin signaling pathway. An important factor is the signal transduction through
Akt. Akt activity can be improved with appropriate levels of omega-3 and DHA, which can
help reduce βA levels and amyloid burden, as has been observed in transgenic mice Tg2576
regulating the activity of the enzyme IDE [22]. The loss of inhibition of GSK3 is involved in
the production of neurofibrillary tangles and tau aggregation, which leads to oxidative
stress, damage and toxicity in the neuronal synapses, so that GSK3 inhibitors could be used
to prevent hyperphosphorylation of tau and the production of neurofibrillary tangles. Insu‐
lin has been used to improve memory and learning in healthy subjects and also in behavio‐
ral tasks in rats, suggesting a role in enhancing memory in humans, however, the actual
effects of insulin on the CNS are just being elucidated [23,24].
Figure 3. Insulin can enter the brain through the blood barrier by active transport mediated by IR. The IR is found
abundantly in the hippocampus and synapses of dendritic trees, wich regulates the release of neurotransmitters and
receptor recruitment. Insulin regulates glutamatergic and GABAergic receptors throug PI3K and MAPK [126].
Among the compounds which have been proposed as reducing agents include βA charging
the statins, which lower cholesterol levels, some peptides that prevent Aβ fibril formation as
PBT-531 and NC-1 (a chelating metals) and modulators of the activity of the secretases as
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Bryostatin. Finally, the use of antioxidants such as vitamin E, have shown effectively to
counter the effects of oxidative stress produced in the EA [25].
4. Proteins involved in cholesterol metabolism
Cholesterol, the most common steroid in humans, is a structural component of cell mem‐
branes and is a precursor of steroid hormones and bile salts. Since an excess of cholesterol is
a major risk factor for the development of cardiovascular disease, it is essential a balance be‐
tween cholesterol synthesis, uptake, and catabolism. Cholesterol is only synthesized in the
liver and brain. The brain contains about 20% of total body cholesterol but only 2% of total
body weight. The majority of this cholesterol is found in myelin membranes. Brain choles‐
terol is synthesized exclusively by de novo synthesis reaction from acetyl-CoA and acetoace‐
tyl-CoA to form HMG-CoA. Then, is converted to mevalonate by HMG-CoA reductase, in
the rate-limiting step of the process by oligodendrocytes, astrocytes and neurons [26].
After synthesis and secretion from glia via the ABCA1 transporter, cholesterol is packaged
into lipoprotein particles resembling HDL. These HDL particles contain apoE. HDL is taken
up into neurons through recognition of ApoE by a variety of lipoprotein receptors including
the LDL receptor (LDLR); the LDL receptor related protein (LRP), the apoE receptor, as well
as other lipoprotein receptors. Elimination of cholesterol from the brain occurs mainly via
oxidation at the 24 and 27 positions to produce a class of compounds termed oxysterols. Wa‐
ter solubility of oxysterols is higher than cholesterol and diffuse across the BBB where they
enter the peripheral circulation for excretion. In vitro studies showed a cholesterol shuttle
from astrocytes to neurons that is mediated by apoE [27]. Virtually no cholesterol crosses the
blood brain barrier from the peripheral circulation. Therefore, serum cholesterol levels have
no effect on HMG-CoA reductase and its activity in the brain [28], and on total brain choles‐
terol levels [29]. The plasma half-life of cholesterol is several hours and fluctuates signifi‐
cantly according to intake. By contrast, cholesterol in the CNS is metabolized slowly, with a
half life of 6 months in rats, and about 1 year in humans. In fact, changes in serum cholester‐
ol have low impact on the CNS. Cholesterol metabolism in the brain is regulated by apoE4
and 24-hydroxylase. The rate-limiting enzyme 24-hydroxylase is uniquely expressed in the
brain, and modulates the removal of cholesterol from the brain. The gene encoding this en‐
zyme is called CYP46, and the CYP46 polymorphism was found to be associated with an in‐
creased Aβ deposition and tau phosphorylation, as well as with a higher risk of late-onset
AD [30,31]. Cholesterol 24-hydroxylase (Cyp46) related to cytochrome P450, the ABC trans‐
porter (ABCA1), the receptor-associated protein to LDL (LRP) and the -2-macroglobulin.
LRP1 is expressed mainly in neurons and activated astrocytes [32], and directly binds free
Aβ, and mediates its egress from the brain [33]. Furthermore, it has been suggested that γ-
secretase-mediated processing of APP plays a regulatory role in brain cholesterol and apoE
metabolism through LRP1 [34]. In addition, the LRP polymorphism is negatively associated
with Alzheimer. The Cyp46 is a brain specific enzyme that oxidizes cholesterol to form 24
(S)-hydroxycholesterol and its function is to remove cholesterol from the brain. Moreover,
statins have been linked with AD, because the subjects medicated with them have lower
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prevalence of the disease [35]. The LRP-associated protein binds to LDL receptor very prom‐
inent in neurons. The α 2-macroglobulin is a protein capable of binding Aβ with high specif‐
icity and preventing its fibrillization [36]. α2M is found in neuritic plaques in AD brain [37]
and it may play a role in Aβ clearance via LRP, as it is known to be able to bind other li‐
gands and target them for internalization and degradation [38]. However, the putative role
of these molecules in AD is controversial because some studies have failed to show an asso‐
ciation between polymorphisms of α 2-macroglobulin and AD [39,40].
Studies in vitro showed that cholesterol depletion after treatment with both statins and
methyl-β-cyclodextrin, which physically extracts membrane cholesterol, inhibits the genera‐
tion of Aβ in hippocampal cells [41,42]. In transgenic AD animal models, hypercholesterole‐
mia accelerates the development of Alzheimer’s amyloid pathology [43]. Cholesterol-fed
rabbits also develop changes in their brain that are typical of AD pathology [44].
Clinic-epidemiological  studies  suggest  that  increased  serum  cholesterol  levels  did  not
correlate substantially with AD in older ages [45,46].  However, all  epidemiological stud‐
ies,  genetic,  metabolic  and  laboratory  show  that  many  factors  regulation  of  cholesterol
metabolism are  involved in  the  physiopathology of  AD.  The  most  prevalent  risk  factor
identified to date is the Apolipoprotein E4 (Apo-E4), which is a protein carrier of choles‐
terol, Apo-E exists in the brain and the periphery. Although the E4 genotype appears to
confer a risk for AD independent of plasma levels of cholesterol, the data do not clearly
discriminate whether the polymorphism of the Apo E4 contributes to Alzheimer through
a direct effect on Aβ, or an indirect effect through involving the catabolism of cholester‐
ol (Figure 4). The levels of 24-hydroxycholesterol (24-OHC) is increased with age in sub‐
jects  with  AD,  and  recent  studies  suggest  that  genetic  factors  related  to  this  molecule
contribute to the pathogenesis of the disease [47].
Cholesterol catabolites also regulate the processing of the APP. Pharmacological inhibition
of acyl-CoA:cholesterol acyltransferase (ACAT), which produces cholesterol esters, decreas‐
es Aβ. This is significant because the ACAT inhibitors are in development for the pharma‐
ceutical companies for the treatment of atherosclerosis and such drugs may become useful
for testing in AD. On the other hand, synthetic oxysterol, 22-hydroxycholesterol and syn‐
thetic LXR agonist reduces Aβ generation in murine models of AD via elevated apoE pro‐
tein levels and increased lipidation of apoE, rather than through suppression of Aβ
generation [48]. Furthermore, LXR agonist preserves cognitive function at a dose far below
required to observe decreased Aβ levels [49] and AD neuropathology was exacerbated in
mice lacking LXRs, providing further support for the central role of LXR target genes in the
pathogenesis of AD. The enzyme that catalyzes the cleavage of β APP β-secretase is the
(BACE) and their activity is particularly dependent on cholesterol levels [50] (Figure 5).
Studies on the cholesterol use in the brain of AD patients are also significant and consistent;
cholesterol is removed from the brain to become 24-OHC, which appears in the plasma. The
24-OHC levels are increased in patients with AD or any other degenerative disease. The in‐
crease is probably, because cholesterol from degenerating neurons is captured and removed
to maintain homeostasis. It has been shown that neurons with degenerative tangles showed
increased levels of cholesterol. However, there is a striking difference between serum and
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brain levels of 24-OHC in AD, because the first increase; while the latter decrease. This per‐
haps reflects the decline in the number of neurons and synapses in the brains of subjects
who died with AD [47]. Cholesterol is synthesized through a complex route that is blocked
by a class of enzymes generically called statins. The clinical utility of statins has been dem‐
onstrated across multiple epidemiological studies, some of which have suggested that these
drugs might be effective in treating AD disease. Advances in understanding the relationship
between the biology of cholesterol and the production of Aβ peptide, crucial in the develop‐
ment of amyloid plaque, will lead to new therapeutic approaches for AD disease.
Figure 4. In Alzheimer’s Disease (AD) animal models, hypercholesterolemia accelerates the development of Alzheim‐
er’s amyloid protein. Genetic, metabolic, clinical and epidemiological studies have shown that many factors involved
in cholesterol’s metabolism are involved in the pathophysiology of AD. The most prevalent risk factor is the APOE-4
(Apolipoprotein E4) genotype.
Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase, which converts HMG-CoA into mevalonate; this is the rate-limiting step in cho‐
lesterol biosynthesis [51]. These drugs decrease cholesterol levels about 30% and with few
adverse effects. The first statin was lovastatin was synthesized, and since then have ap‐
peared fluvastatin, pravastatin, simvastatin and atorvastatin. Simvastatin and lovastatin are
administered as pro-drugs and must be activated. These drugs differ in their lipid solubility;
lipophilic statins, such as pravastatin, enter cells via an ATP-dependent anion transport sys‐
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tem [52]. Pravastatin was not previously thought to cross the blood-brain barrier, however,
it was recently demonstrated in mice that oral pravastatin treatment results in measurable
pravastatin levels in the brain [53]. Pravastatin use is associated with a reduced risk of AD
[54,55]. Statins inhibit cholesterol synthesis but also seem to affect other processes, because
they can increase apoptosis and alter neuronal proliferation. Also decrease the immune re‐
sponse, anti-inflammatory property that has made recently has made the proposal to treat
multiple sclerosis. Also appear to inhibit bone turnover and thereby reduce osteoporosis.
The probable protective effects of statins in AD seem stronger than any association between
plasma cholesterol and disease.
Figure 5. The inhibition of Acetyl-CoA and Acetoacyl-CoA (ACAT) produces cholesterol esters and decreases Amyloid
Beta (AB). Synthetic oxysterol, 22-hydroxychoresterol and synthetic LXR agonists reduce AB generation in murine
models of AD via elevated ApoE protein levels and increased lipidation of ApoE [124].
Oral administration of statins, in addition to inhibiting cholesterol synthesis, also affects
gene expression the mouse brain [53]. Therefore, statins may protect the brain from AD by a
mechanism independent of their effect on cholesterol. In addition to inhibition of cholesterol
synthesis, statins block mevalonate formation and subsequently prevent formation of iso‐
prenoids such as famesylpyrophosphate and geranylpyrophosphate. Statins inhibit isopre‐
nylation of proteins, including the Rho family of small GTPases, in neuronal cells [56] and
cultured microglia [57,58]. RhoA is a monomeric G-protein that is negatively coupled to cell
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growth; prevention of RhoA isoprenylation increases neurite extension [59]. At this regard,
treatment of neurons with pravastatin enhanced neurite number, length and branching, and
that this effect is mediated by inhibition of mevalonate synthesis and subsequent inhibition
of isoprenylation of Rho GTPases and subsequent prevention of neuritic dystrophy and de‐
terioration [60].
Epidemiological studies have found an inverse relationship between usage of the choles‐
terol-lowering  drugs  and risk  of  developing  AD [54,55,61].  Statins  are  inhibitors  of  the
enzyme  HMG-CoA  reductase,  which  converts  HMG-CoA  into  mevalonate;  this  is  the
rate-limiting step in cholesterol  biosynthesis  [51].  However,  reduction of  cholesterol  lev‐
els  may  or  may  not  correlate  with  reduced  risk  of  AD  in  patients  taking  statin  drugs
[62-64].  Furthermore,  statin usage is  associated with a  decreased risk of  depression and
anxiety,  which is  not  correlated with plasma cholesterol  levels  [65].  Oral  administration
of  statins,  in  addition to  inhibiting cholesterol  synthesis,  also  affects  gene expression in
the  mouse  brain  [53].  Thus,  statins  might  prevent  onset  of  AD  by  a  mechanism  inde‐
pendent of their effect on cholesterol.
Apolipoprotein E (apoE) is the major apolipoprotein in the brain and is a structural com‐
ponent  of  triglyceride-rich  lipoproteins,  chylomicrons,  very-low-density  lipoproteins
(VLDL), and high-density-lipoproteins (HDL). ApoE is synthesized and secreted from as‐
trocytes and microglia. Variation in the APOE gene sequence results in the 3 common al‐
leles (ε2, ε3 and ε4), which can produce 6 different genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3,
ε3/ε4  and ε4/ε4).  The ε2,  ε3  and ε4  alleles  encode three  distinct  forms of  apoE (E2,  E3
and E4) that differ in their amino acid composition at positions 112 and 158 [66]. ApoE3
seems to be the normal isoform, while apoE4 and apoE2 can each be dysfunctional [67].
Inheritance of apoE4 is associated with a greater risk of developing AD at an earlier age
[68], whereas inheritance of apoE2 correlates with lower risk and later onset of AD [69].
individuals with the APOE ε4 allele show higher levels of plasma cholesterol,  especially
LDL cholesterol  [70].  Subjects  with  APOE ε3/ε4  and ε4/ε4  genotypes  absorb  cholesterol
effectively and have higher non-fasting serum triglyceride values than ε4 negative indi‐
viduals [71,72]. A ApoE gene mutation (allele 4), the main risk factor for AD, may influ‐
ence  the  risk  of  dementia  more  strongly  among  those  with  diabetes,  in  fact,  findings
from population studies show that people with diabetes and ApoE 4 are at greatest risk
of  AD  compared  with  those  without  diabetes  and  without  the  ApoE  4.  Although  we
know that people with diabetes are at increased risk of stroke, little is known about the
effect of diabetes on the pathophysiology of neurodegeneration.
5. Membrane fluidity in Alzheimer disease
The role of the physical–chemical properties of intracellular membranous structures such as
membrane fluidity in AD pathogenesis has been extensively studied. Membrane fluidity is a
complex parameter, influenced both through some biophysical (temperature, electrical
charges, pH) and biochemical factors (protein/phospholipids ratio, phospholipids/cholester‐
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ol ratio, degree of fatty acids unsaturation). It is a parameter that reflects the main mem‐
brane characteristic organization (gel or liquid crystal structure). Experiments provide
consistent data about membrane fluidity relations to various cellular processes, especially
membrane processes. Changes in the membrane composition and structure could alter the
conformation and function of transmembranal ion channels, as well as affect the interaction
of receptors and effectors, leading to altered signal transduction, handling of Ca”, and re‐
sponse to exogenous stimuli [73].
Cholesterol distribution within the plasma membrane is not homogeneous: the highest level
of free cholesterol inside the plasma membrane is found in cytofacial bilayer leaflet [74]. The
exofacial leaflet contains substantially less cholesterol, and it is mostly condensed in lipid
rafts, which are more tightly packed than nonlipid raft domains due to intermolecular hy‐
drogen bonding involving sphingolipid and cholesterol [75]. This asymmetric distribution
of cholesterol is altered by aging: it is significantly increased in exofacial leaflet with increas‐
ing age [76,77]. It has been reported that membrane fluidity of lipid membranes in the brain
cortex of AD samples were significantly thinner (that is, had less microviscosity) than corre‐
sponding age-matched controls. This change in membrane width correlated with a 30% de‐
crease in the ratio cholesterol/ phospholipid [78].
In our group of research we assessed the membrane fluidity in platelet submitochondrial
particles and erythrocyte membranes from Mexican patients with Alzheimer disease. Sub‐
mitochondrial particles are mainly constituted of inner mitochondrial membrane and are the
site of oxidative phosphorylation and other enzymatic systems involved in the transport
and utilization of metabolites. Membrane fluidity was estimated measuring the intramolecu‐
lar excimer formation of the fluorescent probe 1,3 dipyrenylpropane incorporated in mem‐
branes. Similarly to the data reported from mitochondria in AD brains fluidity [79]., a
reduced fluidity in the platelet inner mitochondrial membrane was found. It can partially be
due to increased levels of lipid peroxidation [80]. Reduced membrane fluidity can diminish
the activities of the enzymes of oxidative phosphorylation and other transport and receptor
proteins, in as much as these enzymes are regulated by the physicochemical state of the lipid
environment of the membrane. It may diminish significantly the ATP generation from the
mitochondria. Interestingly, dysfunctional mitochondria and oxidative damage has been in‐
volved in Alzheimer’s disease [81]. In agreement with previous reports, membrane fluidity
from erythrocyte was not altered in AD [82], regardless of increased lipid oxidation in eryth‐
rocyte AD patients. This suggests that, in AD, mitochondrial membranes are more sensitive
to oxidative stress than erythrocytes. In contrast to platelet inner mitochondrial membrane,
it has been reported an increase in fluidity in whole membranes from platelets of AD pa‐
tients [83]. This increase results from the elaboration of an internal membrane compartment
resembling endoplasmic reticulum that is functionally abnormal [84]. At this regard, it is
worth noting that the contribution of mitochondrial membranes to the whole cell mem‐
branes in platelets could be minimized since platelets contain few mitochondria [85].
On the other hand, it has been reported that using diphenil-hexatriene (DPH) and trimethy‐
lammonium-diphenyl-hexatriene (TMA-DPH) as fluorescent probes, the membrane fluidity
in mitocondrial membranes was similar in platelets from AD patients and controls [86]. That
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discrepancy with our data may be due to intrinsic differences in the populations tested, the
purity of the used mitochondrial fraction and the nature of the probes used. Additionally,
it’s clear that the lipophilic probes are sensitive to slightly different membrane properties.
For instance, DPH and TMA-DPH are rotational probes [87] and dipyrenylpropane is a lat‐
eral diffusion sensitive probe [88]. In addition, DPH partitions into the interior of the bilayer
and its average location has been shown to be about 8 Å from the center of the bilayer.
TMA-DPH is oriented in the membrane bilayer with its positive charge localized at the lip‐
id-water interface. Its DPH moiety is localized at about 11 Å from the center of the bilayer
and reports the interfacial region of the membrane [89]. Whereas dipyrenylpropane is a
highly hydrophobic probe which partitions into the membrane lipid bilayer [88].
As shown in figure 1, we found a significant decrease of membrane fluidity in hippocampal
neurons from AD patients compared with membranes from elderly non demented controls
(Figure 6). Lower membrane fluidity in AD patients was correlated with abnormal APP
processing and cognitive decline [90].
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Figure 6. Excimer to monomer fluorescent ratio of dipirenylpropane on plasma membrane of hippocampus fom AD
patients and aged-matched controls. The fluorescent probe was excited at 329 nm and emission of monomer (Ie) and
excimer (Im) was read at 379 and 480 nm, respectively. Intramolecular excimer formation of this probe is related with
the membrane fluidity. Therefore the ratio (Ie/Im) is directly proportional to membrane fluidity, which is reciprocal to
membrane viscosity. The data shown are mean ± S.E.M. ∗p <0.01.
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Some strategies for the preservation of membrane fluidity include the use of polyunsaturat‐
ed fatty acid (PUFAs). The brain is particularly rich in PUFAs such as eicosapentaenoic
(EPA) and docosahexaenoic acids (DHA). PUFAs play an essential role in the normal devel‐
opment and functioning of brain [91]. Diets enriched in n-3 PUFA increased membrane
fluidity, affect signal transduction and modulate gene expression for brain function [92].
Furthermore, DHA have the following effects: maintains membrane fluidity, improved syn‐
aptic and neurotransmitter functioning, enhanced learning and memory performances and
displayed neuroprotective properties [93], decreased the amount of vascular Aβ deposition
[94] and reduced Aβ burden [22]. In AD mouse model, DHA modulated APP processing by
decreasing both α- and β-APP C-terminal fragment products and full-length APP [22]. How‐
ever, caution should be taken when PUFAs are used for dietary supplementation, since
DHA could be increasing oxidative stress, resulting in lipid peroxidation [95,96].
Addition of cholesterol restored the membrane width to that of the age-matched control
samples. Alterations in other membrane components of AD brains have also been reported.
The cholesterol content in lipid rafts has been shown to contribute to the integrity of the raft
structure and the functions of the rafts in signaling and membrane trafficking [97]. At this
regard, it has been shown that cholesterol depletion leads to increased membrane fluidity
[98] mainly in intracellular membranes [99] and reduced endocytosis, shifting sAPP shed‐
ding from β-cleavage towards α-cleavage [63]. In fact, the cleavage of APP by β-secretase
[100], occurs mainly in highly ordered membrane microdomains dispersed at the cell sur‐
face. These microdomains known as lipid rafts are enriched in cholesterol, sphingolipids
and saturated phospholipids. Lipid rafts appear to be a mechanism to compartmentalize
various processes on the cell surface by bringing together various receptor-mediated and
signal transduction processes. The cleavage of APP by α-secretase is done mostly in nonraft
domains [101]. Furthermore, it has been shown in vitro that lowering cholesterol leads to de‐
creased BACE-cleavage of APP [102,103] and increased α-cleavage of APP [102].
Increased membrane fluidity due to cholesterol depletion inhibits endocytosis which might
explain the observed increase of sAPPα and shift towards α-secretase cleavage that happens
on the cell surface. Cholesterol increase is associated with enhanced membrane stiffness pos‐
sibly explaining the disrupted proximity of APP and BACE. Surprisingly this is associated
with enhanced sAPPβ production, possibly explained by altered transport and endocytosis
mechanisms [103]. Another explanation therefore is the direct impact of cholesterol environ‐
ment upon BACE activity. In living cells, BACE seems to require intact rafts for activity, and
BACE outside rafts seems to be inactive [104].
6. Role of dietary lipids in Alzheimer disease
Recent theories suggests that there would be an interaction between genetic predisposition
and environmental factors that lead to cell death by amyloid toxicity or disruption of tau
protein. Dietary lipids could be a determining factor in the difference in risk between devel‐
oped and underdeveloped countries. Dietary lipids could be the primary risk factor in late-
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onset sporadic AD (LO-SAT). The critical factors seem to be the ratios of polyunsaturated
fatty acids (PUFAs) to monounsaturated (MUFA), saturated fatty acids (SFA) to essential
fatty acids (EFAs). These contents are modified by the APOE4 genotype [105].
Oxidation  of  neuronal  lipid  membranes  could  be  the  initiating  event  in  the  cascade  of
synergistic  processes  with  subsequent  expression  of  Aβ and helical  filaments  of  hyper‐
phosphorylated  tau  protein.  PUFAs are  important  in  modulating  the  inflammatory  bal‐
ance/systemic  anti-inflammatory  eicosanoids  and  fluidity  and  membrane  function.
Proinflammatory eicosanoids are derived from arachidonic acid (AA). The anti-inflamma‐
tory  eicosanoids  are  derived  from the  via  the  n-3  EFA through DHA)  and  EPA.  EFAs
cannot be synthesized by animals and must be obtained from food. A diet rich in linole‐
ic  acid promotes proinflammatory state,  while  a  diet  rich in linolenic  acid promotes in‐
flammatory  components.  When  lipids  are  exposed  to  free  radicals  begin  an
autoperoxidative  process.  This  process  is  perpetual  and  changes  the  composition  and
rate of membrane lipids with loss of PUFA compared with MUFA and SFA. This causes
the membrane to become less fluid and affecting the function of components, as well as
of  intracellular  organelles  and the vascular endothelium [106].  This  seems to be the ini‐
tial  process  of  the  cascade that  culminates  in  neuronal  death and neuropathological  se‐
quelae  associated  with  LO-SAT.  Antioxidant  vitamins  and  vegetables  may  reduce  the
risk of  AD. High levels of  blood lipids are associated with atherosclerosis and diabetes,
both risk factors for EA indirect.  Recently it  was found that the increase in LDL choles‐
terol, along with APOE epsilon4 genotype is associated with increased risk of AD [107].
The oxidative state of lipid membranes can have effects on neurons, at three levels:a) vascu‐
lar;b) endothelial cell membrane; and c) membrane organelles.At the level of cellular mem‐
branes lipid oxidation accelerates the aggregation of amyloid which consequently decreases
membrane fluidity. This also is observed with decreases of the content of MUFA and PUFA
esterified to phospholipid. Interestingly, these changes are seen in brain regions affected in
AD, especially at the hippocampus. The decrease of the membrane fluidity affects the syn‐
aptic connections [108]. The EA may be preventable and treatable and possibly reversible to
some extent, if the proposed hypothesis is correct. The changes in the fat composition of the
diet are reflected in plasma lipids and phospholipids in the membrane of red blood cells,
likewise in the neural cell membranes, especially in areas of rapid lipid turnover. A diet low
of n-6 PUFA and MUFA, and an adequate amount of n-3 PUFA, but not too caloric, with
antioxidants should protect neuronal damage, lipid oxidation and the inflammatory cascade
and amyloid deposition.
Lipid lowering agents appear to have a protective effect, although studies are not conclu‐
sive. Statins decrease the oxidizability of LDL, with decreased levels of oxygen reactive spe‐
cies, anti-inflammatory effects and improve endothelial dysfunction, also increased alpha-
secretase activity. Increase the synthesis of LDL receptors, with decreased circulating level
and reduced production of PPA.
The histological changes seen in the initial stages of AD confirmed that membrane lipids
and inflammation are  involved in  the  disease  (Figure  7).  AGE n-3/n-6  rate  has  a  major
impact  on  the  balance  of  eicosanoid  metabolism  inflammatory  and  anti-inflammatory,
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and  the  degree  of  saturation  of  membrane  lipids  and  fluidity  affects  its  function.  The
apoE4 genotype may influence the risk of  AD, as it  is  unable to protect  that  transports
lipids from oxidation [109].
Figure 7. Cellular changes induced by lipid oxidation linked to dietary lipids. The change in dietary intake of lipids
causing a low PUFA/MUFA (Polyunsaturated Fatty Acid/Monounsaturated Fatty Acids) ratio, which finally altered syn‐
aptic connections and neuron collapse [127].
7. Membrane phospholipid metabolism
The  principal  constituents  of  mammalian  cell  membranes  are  phospholipids,  the  most
abundant of which is phosphatidylcholine (PC). PC biosynthesis is initiated by the phos‐
phorylation  of  choline  to  form phosphocholine,  which  then  combines  with  cytidine  tri‐
phosphate  (CTP)  to  form  5'-cytidine  diphosphocholine  (CDP-choline);  this  compound
then reacts with diacylglycerol (DAG) to produce PC [110]. The rate at which cells form
PC is affected by the availability of its precursors. Thus, uridine or cytidine increase CTP
levels  [111];  availability  of  CTP  levels  in  turn  can  be  rate-limiting  in  the  syntheses  of
CDP-choline [112] and PC [113]; and DAG levels can control the conversion of CDP-chol‐
ine to PC [114]. AD is also associated with abnormal metabolism of membrane phospho‐
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lipids. Alterations in the metabolism of the phospholipids phosphatidylcholine (PC) have
been detected in the cerebrospinal fluid of AD patients [115]. Neural membrane glycero‐
phospholipids,  particularly  ethanolamine  plasmalogens,  are  markedly  decreased  in  au‐
topsy  samples  from  AD  brain  compared  to  age-matched  control  brain  [116].  This
decrease in glycerophospholipids is accompanied by a marked elevation in phospholipid
degradation metabolites such as glycerophosphocholine,  phosphocholine,  and phosphoe‐
thanolamine [117]. Furthermore, marked increases have been reported in levels of prosta‐
glandins  and  lipid  peroxides  in  AD  brain  [118,119].  The  marked  changes  observed  in
phospholipids  and their  catabolic  products  may be coupled to  the  elevated activities  of
lipolytic  enzymes  in  AD brain  [120].  Moreover,  cortices  of  AD patients  have  decreased
levels  of  PC and phosphatidylethanolamine,  compared with age-matched controls  [116].
PC synthesis  is  regulated  by  levels  of  its  precursors  [113,114];  therefore,  stimulation  of
PC synthesis by increasing precursor levels prevents the disruption in normal phospholi‐
pid  metabolism  caused  by  AD.  Furthermore,  increasing  cell  membrane  synthesis  may
have  morphological  consequences  for  the  cell.  For  instance,  dendritic  atrophy  and  loss
occur in mouse models of AD [121,122] and dystrophic neurites are observed in human
cases of AD [123]
8. Concluding remarks
Data from a series  of  biochemical,  genetic,  epidemiological  studies  and others  exhibited
that cholesterol is a key factor in APP processing and Aβ production. For instance, high
cholesterol  levels  are  linked to  increased Aβ generation and deposition.  It  appears  that
there are many different  ways in which abnormalities  in cholesterol  metabolism can af‐
fect  the  development  of  AD.  Some polymorphisms in  genes  involved in  cholesterol  ca‐
tabolism  and  transport  have  been  associated  with  an  increased  level  of  Aβ  and  are
therefore potential  risk factors for the disease.  The best  known of these genes is  apoE4,
which is  the major  genetic  risk factor  known for late-onset  AD. Other genes implicated
include cholesterol 24-hydroxylase (Cyp46), the LDL receptor related protein, the choles‐
terol  transporter  ABCA1,  acyl-CoA:cholesterol  acetyl  transferase,  and  the  LDL receptor.
Then, we may conclude that what is bad for the heart is bad for the brain. We must pay
attention to risk factors associated with heart disease to prevent Alzheimer's disease also.
Considerable interest  has also arisen regarding the effects  of  lifestyle  interventions such
as exercise and dietary/nutriceutical manipulations.
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